Andrew J. Brooks
Physics and Astronomy · Indiana University
Publications
191
Citations
4,321
Est. group size
—
Recurring co-author estimate
Active years
48
Publishing since 1979
Andrew J. Brooks studies how cells send and receive chemical signals, focusing on cytokine and growth-hormone receptors (such as GP130 and the growth hormone receptor) and the enzymes (kinases) that control their activity. Much of this work connects to cancer immunotherapy, including engineering immune cells like natural killer (NK) cells and antibody-based approaches to target tumors. The research spans molecular mechanisms of receptor signaling through to potential clinical applications.
Publication activity has been relatively steady but modest over the last decade, averaging about 3.4 papers per year in the most recent five years, down from higher counts earlier in the period.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Transmembrane orientation and extracellular juxtamembrane residues of GP130 are critical for signal transduction
The Journal of Immunology · 2026
- Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR
Clinical and Translational Medicine · 2025
- TLR4 endocytosis and endosomal TLR4 signaling are distinct and independent outcomes of TLR4 activation
EMBO Reports · 2025
- Harnessing cytokine immunocomplexes and cytokine fusion proteins for cancer Therapy: Mechanisms and clinical potential
Cancer Treatment Reviews · 2025
- Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy
Molecular Therapy · 2025
- The heavy subunit of ferritin stimulates NLRP3 inflammasomes in hepatic stellate cells through ICAM-1 to drive hepatic inflammation
Science Signaling · 2024
- A scalable, spin‐free approach to generate enhanced induced pluripotent stem cell–derived <scp>natural killer</scp> cells for cancer immunotherapy
Immunology and Cell Biology · 2024
- Squamous cell carcinoma is associated with reduced IL34 expression, alterations in the Langerhans cell antigen‐processing‐presentation machinery and poor patient survival
Clinical & Translational Immunology · 2024
- Roles of Growth Hormone–Dependent JAK-STAT5 and Lyn Kinase Signaling in Determining Lifespan and Cancer Incidence
Endocrinology · 2024
- Abstract A001: Epithelial cancers demonstrate IL34-associated dysfunction of Langerhans cells
Cancer Immunology Research · 2024
- Location, location, location: Protein kinase nanoclustering for optimised signalling output
eLife · 2023
- Tyrosine kinases compete for growth hormone receptor binding and regulate receptor mobility and degradation
Cell Reports · 2023
- 68 The Diurnal and Seasonal Relationships of Young Pedestrian Injuries Secondary to Motor Vehicles
British journal of surgery · 2023
- Location, Location, Location: Protein kinase nanoclustering for optimized signalling output
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Author Correction: Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands
Nature Communications · 2023
- Nature Communications×4
- Endocrinology×4
- Blood×3
- ANZ Journal of Surgery×3
- Developmental Cell×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile